Oncovir

Executive Summary

Oncovir is a clinical-stage biotechnology company pioneering Hiltonol® (Poly ICLC), a synthetic double-stranded RNA viral mimic and immunomodulator. Hiltonol activates innate and adaptive immunity through Toll-like receptor 3 (TLR3) and other pathways, positioning it as a promising cancer immunotherapy and vaccine adjuvant. The company has advanced Hiltonol into multiple Phase 2/3 trials across oncology indications, including glioblastoma and head and neck squamous cell carcinoma, and is exploring its potential in infectious disease vaccines. As a private company with no disclosed funding history or valuation, Oncovir faces typical clinical-stage risks, including capital requirements and regulatory milestones. The platform's broad immunomodulatory mechanism offers potential for combination therapies and pandemic preparedness, but successful execution of ongoing trials and securing partnerships are critical for near-term value creation.

Upcoming Catalysts (preview)

• Q1 2027Phase 2/3 Data Readout in Glioblastoma (e.g., Hiltonol + Temozolomide)30% success
• Q3 2026FDA Authorization for Investigational New Drug (IND) in Infectious Disease Adjuvant60% success
• Q4 2026Strategic Partnership or Licensing Deal for Vaccine Adjuvant Platform40% success